Parvovirus-like particles as vaccine vectors.
A wide array of systems have been developed to improve "classic" vaccines. The use of small polypeptides able to elicit potent antibody and cytotoxic responses seems to have enormous potential in the design of safer vaccines. While peptide coupling to large soluble proteins such as keyhole limpet hemocyanin is the current method of choice for eliciting antibody responses and insertion in live viruses for cytotoxic T-lymphocyte responses, alternative cheaper and/or safer methods will clearly be required in the future. Virus-like particles constitute very immunogenic molecules that allow for covalent coupling of the epitopes of interest in a simple way. In this article, we detail the methodology employed for the preparation of efficient virus vectors as delivery systems. We used parvovirus as the model for the design of new vaccine vectors. Recently parvovirus-like particles have been engineered to express foreign polypeptides in certain positions, resulting in the production of large quantities of highly immunogenic peptides, and to induce strong antibody, helper-T-cell, and cytotoxic T-lymphocyte responses. We discuss the different alternatives and the necessary steps to carry out this process, placing special emphasis on the flow of decisions that need to be made during the project.
Casal
J I
JI
INGENASA, Hnos. Garcia Noblejas 41, 4 degrees, Madrid, 28037, Spain. icasal@ingenasa.es
Rueda
P
P
Hurtado
A
A
D000818:Animals; D016367:Baculoviridae / Q000235:genetics; D001483:Base Sequence; D002678:Chimera / Q000235:genetics / Q000276:immunology; D004279:DNA, Viral / Q000235:genetics; D005822:Genetic Vectors; D006801:Humans; D008969:Molecular Sequence Data; D016296:Mutagenesis; D017992:Parvovirus / Q000235:genetics* / Q000276:immunology* / Q000302:isolation & purification; D014614:Vaccines, Synthetic / Q000235:genetics* / Q000302:isolation & purification; D014771:Virion / Q000235:genetics / Q000276:immunology
D004279:DNA, Viral; D014614:Vaccines, Synthetic